| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| conatumumab | cannabinoid receptor 1 | NA | Successful target | TTD , DGIDB | Colorectal Cancer[MeSHID:D015179] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Pain[MeSHID:D010146] |
0.41 | phase 2 | unknown |
| conatumumab | voltage-gated sodium channel alpha nav1.8 | NA | Successful target | TTD , DGIDB | Colorectal Cancer[MeSHID:D015179] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Pain[MeSHID:D010146] |
0.21 | phase 2 | unknown |
| conatumumab | trail receptor 2 | NA | Clinical trial target | TTD , DGIDB | Colorectal Cancer[MeSHID:D015179] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Pain[MeSHID:D010146] |
9.09 | phase 2 | antibody |
| conatumumab | trail receptor 2 | NA | Clinical trial target | TTD , DGIDB | Colorectal Cancer[MeSHID:D015179] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Pain[MeSHID:D010146] |
9.09 | phase 2 | agonist |
| conatumumab | trail receptor 2 | NA | Clinical trial target | TTD , DGIDB | Colorectal Cancer[MeSHID:D015179] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Pain[MeSHID:D010146] |
9.09 | phase 2 | unknown |
| click here to return to the previous page | ||||||||